1. Home
  2. DOMO vs GNLX Comparison

DOMO vs GNLX Comparison

Compare DOMO & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Domo Inc. Class B

DOMO

Domo Inc. Class B

N/A

Current Price

$3.84

Market Cap

132.7M

Sector

Technology

ML Signal

N/A

Logo Genelux Corporation

GNLX

Genelux Corporation

N/A

Current Price

$2.41

Market Cap

110.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DOMO
GNLX
Founded
2010
2001
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
132.7M
110.4M
IPO Year
2018
2022

Fundamental Metrics

Financial Performance
Metric
DOMO
GNLX
Price
$3.84
$2.41
Analyst Decision
Buy
Strong Buy
Analyst Count
9
4
Target Price
$10.28
$17.25
AVG Volume (30 Days)
1.2M
294.1K
Earning Date
05-20-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
31.92
9.47
EPS
N/A
N/A
Revenue
$318,857,000.00
$8,000.00
Revenue This Year
$3.41
N/A
Revenue Next Year
$4.72
N/A
P/E Ratio
N/A
N/A
Revenue Growth
0.57
N/A
52 Week Low
$1.84
$2.29
52 Week High
$18.49
$8.54

Technical Indicators

Market Signals
Indicator
DOMO
GNLX
Relative Strength Index (RSI) 57.42 40.28
Support Level $3.32 $2.34
Resistance Level $4.05 $2.97
Average True Range (ATR) 0.15 0.16
MACD 0.00 -0.01
Stochastic Oscillator 75.31 14.29

Price Performance

Historical Comparison
DOMO
GNLX

About DOMO Domo Inc. Class B

Domo Inc provides a cloud-based platform that digitally connects all the data, systems, and people in an organization, giving them access to real-time data and insights and allowing them to manage their business from their smartphones. The company offers a platform to its customers as a subscription-based service. Users receive notifications on any device and immediately act on the invitation, after which the system can write back to the original system of record. The company derives revenue from subscriptions to its cloud-based platform and professional services.

About GNLX Genelux Corporation

Genelux Corp is a late-stage biopharmaceutical firm focused on developing oncolytic viral immunotherapies for cancer. Its pipeline includes clinical and preclinical candidates designed to target tumor cells and stimulate an immune response against tumor-specific antigens. The company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor's sophisticated defense mechanisms.

Share on Social Networks: